证券代码：688578 证券简称：艾力斯 公告编号：2024-012 上海艾力斯医药科技股份有限公司 关于续聘公司 2024 年度财务及内部控制审计机构的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1、拟续聘的会计师事务所名称：普华永道中天会计师事务所（特殊普通合 伙）（以下简称"普华永道中天"） 2、该事项尚需提交上海艾力斯医药科技股份有限公司（以下简称"公司" 或"艾力斯"）股东大会审议 一、拟续聘会计师事务所的基本情况 （一）机构信息 1 天合伙人数为 291 人，注册会计师人数为 1,710 余人，其中自 2013 年起签署过 证券服务业务审计报告的注册会计师人数为 383 人。 普华永道中天经审计的最近一个会计年度（2022 年度）的收入总额为人民 币 74.21 亿元，审计业务收入为人民币 68.54 亿元，证券业务收入为人民币 32.84 亿元。 普华永道中天的 2022 年度 A 股上市公司财务报表审计客户数量为 109 家， A 股上市公司财务报表审计收费总额为人民币 5.29 ...

证券代码：688578 证券简称：艾力斯 公告编号：2024-015 上海艾力斯医药科技股份有限公司 关于召开 2023 年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2023 年年度股东大会 召开日期时间：2024 年 5 月 16 日 14 点 00 分 召开地点：上海市浦东新区周浦镇凌霄花路 268 号公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 5 月 16 日 至 2024 年 5 月 16 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 股东大会召开日期：2024年5月16日 本次股东大会采用的网络投票系统：上海证券交易所股东大会 ...

第一章 总则 第二章 对外担保对象的审查 第一条 按照建立现代企业制度的要求, 为进一步完善上海艾力斯医药科技股份有限 公司(以下简称"公司")法人治理结构, 规范公司对外担保行为, 依照《中华 人民共和国公司法》《中华人民共和国证券法》《上海证券交易所科创板股票 上市规则》等法律、法规和规范性文件以及《上海艾力斯医药科技股份有限 公司章程》(以下简称"公司章程")的有关规定, 并结合公司具体情况制定本 制度。 第二条 本制度所称对外担保是指公司为他人提供的担保, 包括公司对控股子公司的 担保。 第三条 公司对外担保实行统一管理, 非经公司董事会或股东大会批准, 任何人无权 以公司名义签署对外担保的合同、协议或其他类似的法律文件。 第四条 公司董事和高级管理人员应审慎对待和严格控制担保产生的债务风险, 并对 违规或失当的对外担保产生的损失依法承担连带责任。 第五条 公司控股子公司的对外担保, 视同公司行为, 其对外担保应执行本制度。 第六条 公司对外担保应当遵循合法、审慎、互利、安全的原则, 严格控制担保风险。 第七条 公司为他人提供担保, 原则上应当采取反担保等必要的措施防范风险, 反担 保的提供方应具备实 ...

上海艾力斯医药科技股份有限公司 第二届董事会第八次会议决议公告 证券代码：688578 证券简称：艾力斯 公告编号：2024-008 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 董事会会议召开情况 二、董事会会议审议情况 经与会董事审议，形成如下决议： (一)审议通过《关于公司<2023 年年度报告>及其摘要的议案》 经与会董事审议，董事会同意通过《上海艾力斯医药科技股份有限公司 2023 年年度报告》及《上海艾力斯医药科技股份有限公司 2023 年年度报告摘要》。 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）上的 《上海艾力斯医药科技股份有限公司 2023 年年度报告摘要》和《上海艾力斯医 药科技股份有限公司 2023 年年度报告》全文。 表决结果：同意 11 票；反对 0 票；弃权 0 票。 本议案已经公司第二届审计委员会第六次会议及第二届战略委员会第一次 会议审议通过。 本议案尚需提交股东大会审议。 上海艾力斯医药科技股份有限公司（以下简称"公司"）第二届董事会第八 次会议于 ...

上海艾力斯医药科技股份有限公司 2023 年度控股股东及其他关联方占用资金情况专项报告 普华永道 关于上海艾力斯医药科技股份有限公司 控股股东及其他关联方占用资金情况专项报告 普华永道中天特审字(2024)第0935号 (第一页,共二页) 上海艾力斯医药科技股份有限公司董事会: 普华永道 普华永道中天特审字(2024)第0935号 (第二页,共二页) 我们的责任是在执行鉴证工作的基础上对情况表作出结论。我们根据《中国 注册会计师其他鉴证业务准则第3101号 - 历史财务信息审计或审阅以外的鉴证业 务》的规定执行了鉴证工作。该准则要求我们遵守职业道德规范,计划和实施鉴 证工作,以对我们是否发现任何事项使我们相信情况表所载资料与我们审计财务 报表时所审核的会计资料及财务报表中所披露的相关内容在所有重大方面存在不 一致的情况获取保证。在对财务报表执行审计的基础上,我们对情况表实施了包 括核对、询问、抽查会计记录等我们认为必要的工作程序。 根据我们的工作程序,我们没有发现后附由上海艾力斯编制的截至 2023 年 12 月 31 目止年度控股股东及其他关联方非经营性资金占用及其他关联资金往来 情况汇总表所载资料与我们审 ...

上海艾力斯医药科技股份有限公司 （二）是否存在影响独立性的情况说明 作为公司独立董事，我本人及直系亲属、主要社会关系均不在公司或其附属 企业任职；没有直接或间接持有公司已发行股份、不在直接或间接持有公司已发 行股份 5%或以上的股东单位任职、不存在为公司及其控股股东、实际控制人或 者其各自的附属企业提供财务、法律、咨询等服务的情形。具有相关法律法规、 《公司章程》及《独立董事工作制度》所要求的独立性，拥有担任公司独立董事 的任职资格，能够确保客观、独立的专业判断，故不存在影响独立性的情况。 二、独立董事年度履职概况 2023 年度独立董事述职报告（阳佳余） 作为上海艾力斯医药科技股份有限公司（以下简称"公司"）的独立董事， 我在任职期间严格按照《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》、《上海证券交易所科创板股票上市规则》等相关法 律、法规，以及《公司章程》等规定，在 2023 年度工作中，勤勉、尽责、诚信、 独立地履行独立董事的职责，积极出席相关会议，认真审议各项会议议案，切实 维护了公司和股东的利益。现将 2023 年度履行职责的情况述职如下： 一、独立董事的基本情况 ...

证券代码：688578 证券简称：艾力斯 公告编号：2024-011 上海艾力斯医药科技股份有限公司 关于确定原募投项目剩余募集资金用途、部分募投项目结 项并将节余募集资金用于新药研发项目及补充流动资金、 调整新药研发项目的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海艾力斯医药科技股份有限公司（以下简称"公司"或"艾力斯"）于 2024 年 4 月 24 日召开第二届董事会第八次会议、第二届监事会第七次会议，审 议通过了《关于确定原募投项目剩余募集资金用途的议案》、《关于部分募投项目 结项并将节余募集资金用于新药研发项目及补充流动资金的议案》、《关于调整新 药研发项目的议案》，同意确定原募投项目"药物研究分析检测中心项目"剩余 的募集资金全部用于投入"新药研发项目"；同意将募投项目"总部及研发基地 项目"、"营销网络建设项目"以及"信息化建设项目"予以结项，并将结项的节 余募集资金部分用于"新药研发项目"、部分用于补充流动资金；同意调整"新 药研发项目"子项目及部分子项目的投资金额。公司保荐机构中信证券股份有 ...

证券代码：688578 证券简称：艾力斯 公告编号：2024-009 一、利润分配方案内容 经普华永道中天会计师事务所（特殊普通合伙）审计，上海艾力斯医药科技 股份有限公司（以下简称"公司"）2023 年度合并财务报表归属于上市公司股东 的净利润为人民币 644,174,819.25 元，截至 2023 年 12 月 31 日，母公司报表期 末未分配利润为人民币 314,910,229.17 元。经董事会决议，公司 2023 年年度拟 以实施权益分派股权登记日登记的总股本为基数分配利润。本次利润分配方案如 下： 公司拟向全体股东每 10 股派发现金红利 4.0 元（含税）。截至 2023 年 12 月 31 日，公司总股本 450,000,000 股，以此计算合计拟派发现金红利 180,000,000.00 元（含税）。本年度公司现金分红比例占合并报表中归属于上市公司股东的净利 1 每股分配比例：每 10 股派发现金红利人民币 4.0 元（含税）。公司不送红股， 不进行资本公积金转增股本。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期将 在权益分派实施公告中明确。 在实施权益分派的股权登记 ...

Financial Performance - The company's revenue for Q1 2024 reached ¥742,835,715.09, representing a year-on-year increase of 168.65%[4] - Net profit attributable to shareholders was ¥306,052,559.16, showing a significant increase of 777.51% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was ¥301,141,732.04, reflecting a remarkable increase of 1,423.83% year-on-year[4] - Basic and diluted earnings per share were both ¥0.68, marking a substantial increase of 750.00% compared to the previous year[4] - The company achieved operating revenue of RMB 743 million in Q1 2024, a significant increase of 168.65% compared to the same period last year[12] - Net profit attributable to the parent company reached RMB 306.05 million, marking a substantial growth of 777.51% year-over-year[12] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 301.14 million, reflecting an impressive increase of 1,423.83% compared to the previous year[12] - Operating profit for Q1 2024 was CNY 313,917,428.44, compared to CNY 36,685,177.03 in Q1 2023, indicating a substantial increase of about 757.5%[19] - Net profit for Q1 2024 was CNY 306,052,559.16, up from CNY 34,877,411.06 in Q1 2023, reflecting an increase of approximately 775.5%[19] - The company reported a total comprehensive income of CNY 320,044,154.27 for Q1 2024, compared to CNY 34,174,103.40 in Q1 2023, indicating a growth of about 836.5%[19] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥4,376,495,351.66, an increase of 7.40% from the end of the previous year[4] - As of March 31, 2024, total assets amounted to RMB 4.70 billion, an increase from RMB 4.38 billion at the end of 2023[16][17] - The company's cash and cash equivalents stood at RMB 2.40 billion, up from RMB 1.86 billion at the end of 2023[16] - Total liabilities decreased to RMB 379.72 million from RMB 394.22 million at the end of 2023[17] - The equity attributable to the parent company increased to RMB 4.32 billion, compared to RMB 3.98 billion at the end of 2023[17] - Cash and cash equivalents at the end of Q1 2024 totaled CNY 1,919,566,295.01, compared to CNY 374,809,250.57 at the end of Q1 2023, marking an increase of approximately 412.5%[22] Research and Development - Research and development expenses totaled ¥64,126,011.92, accounting for 8.63% of revenue, which is a decrease of 14.35 percentage points year-on-year[4] - Research and development expenses for Q1 2024 were CNY 64,126,011.92, slightly up from CNY 63,535,586.23 in Q1 2023, showing a marginal increase of 1%[18] - The company has received approval for the Phase I clinical trial of its self-developed KRAS G12D selective inhibitor, AST2169, which addresses a significant unmet clinical need[14] Shareholder Information - The top shareholder, Shanghai Qiaoke Enterprise Development Co., Ltd., holds 32.17% of the shares, with a total of 144,776,786 shares[9] - The company has a strong shareholder base, with the top 10 shareholders holding significant stakes, including Chen Xiaofa with 6,721,880 shares[11] Government Support - The company received government subsidies amounting to ¥1,325,609.20 during the reporting period[6] Product Performance - The increase in net profit was primarily driven by a substantial rise in sales of the drug Fumeitini, which was included in the medical insurance list this year[8] - The core product, Furmetin, has been included in the national medical insurance directory, which is expected to positively impact sales performance in 2024[13]

Financial Performance - The company has not achieved profitability since its listing [3]. - The company reported a revenue of RMB 1.5 billion for the fiscal year 2023, representing a year-over-year growth of 20% [11]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion CNY, representing a 25% growth year-over-year [15]. - The total operating revenue for 2023 was CNY 2,018,182,563.12, an increase of 155.14% compared to the previous year, primarily due to the inclusion of the core product, Furmonertinib tablets, in the national medical insurance directory, leading to a significant increase in sales volume [23]. - The net profit attributable to shareholders of the parent company reached CNY 644,174,819.25, representing a growth of 393.54% year-on-year, driven by substantial revenue growth and effective cost control [23]. - The net cash flow from operating activities was CNY 674,649,764.32, an increase of 636.28% compared to the previous year [21]. - Basic earnings per share for 2023 were CNY 1.43, up 393.10% from CNY 0.29 in 2022 [22]. - The company reported a total of CNY 37,990,536.06 in non-recurring gains and losses for 2023 [26]. - The company experienced a significant increase in quarterly revenue, with Q4 2023 revenue reaching CNY 670,380,800.29, marking a continuous growth trend throughout the year [25]. - The company achieved total revenue of 2,018.18 million yuan, a year-on-year increase of 155.14% [29]. - The net profit attributable to the parent company was 644.17 million yuan, up 393.54% year-on-year, while the net profit excluding non-recurring gains and losses reached 606.18 million yuan, reflecting a 663.70% increase [29]. Research and Development - Research and development expenses amounted to CNY 313,059,372.61, a 63.26% increase year-on-year, but the proportion of R&D expenses to operating revenue decreased to 15.51%, down 8.73 percentage points from the previous year [23]. - The company is advancing its research and development efforts, with three new drug applications (NDA) expected to be submitted in the next 12 months [14]. - The company has a robust pipeline with multiple new drug candidates in clinical and preclinical stages, including a fourth-generation EGFR-TKI and PRMT5 inhibitors [39][40]. - The company is conducting multiple clinical trials to explore Furmonertinib's clinical advantages, including a Phase III trial for adjuvant therapy in EGFR mutation-positive NSCLC patients [51]. - The company has developed AST2169, a selective inhibitor for KRAS G12D mutations, which are found in approximately 30% of pancreatic cancer cases, 12% of colorectal cancer cases, and 4% of non-small cell lung cancer cases [54]. - The company is also developing a next-generation EGFR oral small molecule inhibitor (ABK3376), currently in the preclinical stage, with a total investment of approximately ¥2.32 million [84]. - The company’s R&D efforts are focused on achieving best-in-class and first-in-class drug candidates through its core technologies in drug design and optimization [78]. - The company has established a GMP-compliant production facility to ensure effective supply of Furmonertinib [90]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by the end of 2025 [11]. - Market expansion plans include entering two new international markets by Q3 2024, targeting a 15% market share in those regions [15]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 200 million CNY allocated for this purpose [15]. - A strategic acquisition of a biotech firm was completed, enhancing the company's R&D capabilities in oncology [12]. - The company signed a collaboration agreement to obtain exclusive commercialization rights for Pralsetinib capsules in mainland China, which is the first approved RET inhibitor in the region [52]. - The company is actively expanding Furmonertinib's clinical indications through ongoing clinical trials for various patient populations, including those with CNS metastases and rare mutations [51]. Corporate Governance - The company has received a standard unqualified audit report from PwC Zhong Tian [4]. - The company does not have any special arrangements for corporate governance [4]. - The board of directors has fully attended the board meeting [4]. - The company has established various committees under the board, including audit, compensation, and strategy committees, to enhance governance efficiency [147]. - The company has a performance management system in place for senior management, which includes setting clear goals and conducting regular evaluations [200]. - The company has established employee stock ownership plans and other incentive measures to align employee interests with company performance [199]. Risk Factors - The company has detailed various risk factors in its annual report, which can be found in the "Management Discussion and Analysis" section [4]. - The company faces risks related to reliance on a single product and potential market competition, which could affect financial performance [93]. - The company is exposed to regulatory risks due to the highly regulated nature of the pharmaceutical industry, which may affect operational strategies [97]. - The company faced risks related to potential adjustments in the National Medical Insurance Directory, which could impact the market share and sales revenue of Furmonertinib [96]. Employee Development - The company is focused on talent development, implementing a structured training program to enhance employee skills and support sustainable growth [35]. - The company has implemented a digital learning platform, "Aixuetang," to enhance employee training and development [187]. - The company launched an AI coaching system, "Aijiaolian," in 2023 to improve employees' professional knowledge and core information transmission capabilities [187]. - The company has a training system that includes professional courses, general skills courses, and leadership courses for employees at all levels [186]. Profit Distribution - The proposed profit distribution plan for 2023 includes a cash dividend of 4.00 CNY per 10 shares, totaling 180,000,000 CNY, which represents 27.94% of the net profit attributable to shareholders [5]. - The company has established a cash dividend policy, ensuring that at least 10% of the distributable profit is allocated as cash dividends if there are no major investment plans or expenditures [190]. - The cash dividend distribution policy requires a minimum of 80% payout for mature companies without significant capital expenditure plans, and 40% if there are significant expenditures [191]. - The profit distribution proposal must be approved by more than half of the board members before being submitted to the shareholders' meeting for review [192]. - The company engages in regular communication with shareholders, especially minority shareholders, to gather their opinions before the profit distribution plan is reviewed [192].